CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 88,227	$ 25,218
Short-term investments	416,750	708,737
Accounts receivable	5,981	22,492
Inventory	19,202	15,801
Other current assets	15,808	23,333
Total current assets	545,968	795,581
Long-term investments	0	64,828
Property, plant and equipment, net	32,451	60,510
Operating lease right-of-use assets	53,435	117,025
Goodwill	76,501	76,501
Other assets	2,245	2,744
Total assets	710,600	1,117,189
Current liabilities:
Accounts payable	12,980	9,747
Accrued compensation	9,582	15,735
Accrued clinical trial expenses	12,262	26,809
Other accrued expenses	14,713	15,468
Operating lease liabilities, current portion	18,667	17,441
Total current liabilities	68,204	85,200
Operating lease liabilities, less current portion	112,829	125,736
Development derivative liability	0	27,726
Liabilities related to the sales of future royalties, net	155,378	195,427
Other long-term liabilities	7,551	3,592
Total liabilities	343,962	437,681
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated, issued or outstanding at December 31, 2022 or 2021	0	0
Common stock, $0.0001 par value; 300,000 shares authorized; 188,560 shares and 185,468 shares issued and outstanding at December 31, 2022 and 2021, respectively	19	19
Capital in excess of par value	3,574,719	3,516,641
Accumulated other comprehensive loss	(6,907)	(4,157)
Accumulated deficit	(3,201,193)	(2,832,995)
Total stockholders’ equity	366,638	679,508
Total liabilities and stockholders’ equity	$ 710,600	$ 1,117,189